CollPlant Biotechnologies (CLGN) Net Income (2017 - 2026)
CollPlant Biotechnologies' (CLGN) quarterly Net Income came in at -$3.1 million in Q1 2026, down 89.02% YoY from -$28.4 million in Q1 2025, and down 197.13% on a QoQ basis from $3.2 million in Q4 2025.
CollPlant Biotechnologies (CLGN) Net Income (2017 - 2026) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 10 years of Net Income data on file, last reported at -$3.1 million in Q1 2026.
- Quarterly Net Income fell 89.02% year-over-year to -$3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.9 million (down 63.87% YoY) and the FY2025 annual result came in at $11.5 million, down 30.83% from the prior year.
- Net Income fell to -$3.1 million in Q1 2026, from $3.2 million in the prior quarter.
- In the past five years, Net Income ranged from a high of $21.1 million in Q3 2024 to a low of -$16.9 million in Q4 2022.
- A 5-year average of $1.2 million and a median of $283000.0 in 2023 frame the typical range for Net Income.
- Annual changes were most pronounced in 2022 — Net Income plunged 7241.36% — and 2023, when it soared 70749900.0%.
- Tracing CLGN's Net Income over 5 years: stood at -$16.9 million in 2022, then soared by 127.7% to $4.7 million in 2023, then fell by 17.3% to $3.9 million in 2024, then slipped by 17.3% to $3.2 million in 2025, then slumped by 197.13% to -$3.1 million in 2026.
- The last three Net Income figures came in at -$3.1 million (Q1 2026), $3.2 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | CollPlant Biotechnologies | 4.26 Mn | 4.26 Mn | -243,000.00 | -3.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 30, 2026 | -3.12 Mn |
| Dec 31, 2025 | 3.21 Mn |
| Sep 30, 2025 | 3.48 Mn |
| Jun 30, 2025 | 3.35 Mn |
| Mar 30, 2025 | -1.65 Mn |
| Dec 31, 2024 | 3.88 Mn |
| Sep 30, 2024 | 21.14 Mn |
| Jun 30, 2024 | -4.21 Mn |
| Mar 31, 2024 | -4.20 Mn |
| Dec 31, 2023 | 4.69 Mn |
| Sep 30, 2023 | 283,000.00 |
| Jun 30, 2023 | 5.76 Mn |
| Mar 31, 2023 | -3.72 Mn |
| Dec 31, 2022 | -16.93 Mn |
| Sep 30, 2022 | 0.40 |
| Jun 30, 2022 | 12.01 Mn |
| Mar 31, 2022 | -3.86 Mn |
| Dec 31, 2021 | 236,999.58 |
| Sep 30, 2021 | 0.29 |
| Jun 30, 2021 | 7.09 Mn |